Liquidity Events
Biocon to buyback Goldman AIFs’ stake in biosimilars subsidiary with QIP proceeds
Press Release BSE Announcement
Bengaluru-based, publicly listed biopharmaceutical Biocon will use part of the INR 4,500 crore raised from a qualified institutional placement (QIP) issue for purchasing the optionally convertible debentures (OCD) held by Goldman Sachs (via Goldman Sachs India AIF Scheme - 1 and Goldman Sachs India Alternative Investment Trust AIF Scheme - 2) in its subsidiary Biocon Biologics Ltd.
In Nov 2020, Goldman Sachs had invested INR 1,125 Cr via OCDs in Biocon Biologics, the biosimilars focused subsidiary of publicly-listed Biocon Ltd.
Want to receive such news items in your inbox? Click Here to sign up for a trial.
